Literature DB >> 11308186

Combined off-pump coronary surgery and right lung resections through midline sternotomy.

M A Mariani1, W J van Boven, V A Duurkens, S M Ernst, H A van Swieten.   

Abstract

Concomitant severe coronary artery disease and lung malignancies are uncommon. Combining conventional coronary surgery with cardiopulmonary bypass with lung resection is still a controversial issue. Conversely, combining off-pump coronary surgery with right lung resections through a midline sternotomy can be an attractive approach. Off-pump coronary surgery avoids the risks of cardiopulmonary bypass, reduces systemic inflammatory response and does not affect the immune system. We report a series of three patients successfully operated using this approach.

Entities:  

Mesh:

Year:  2001        PMID: 11308186     DOI: 10.1016/s0003-4975(00)02355-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Simultaneous surgery in patients with both cardiac and noncardiac diseases.

Authors:  Yang Yang; Feng Xiao; Jin Wang; Bo Song; Xi-Hui Li; Jian Li; Zhi-Song He; Huan Zhang; Ling Yin
Journal:  Patient Prefer Adherence       Date:  2016-07-18       Impact factor: 2.711

2.  Perioperative outcomes of combined heart surgery and lung tumor resection: a systematic review and meta-analysis.

Authors:  Shizhao Cheng; Yiyao Jiang; Xin Li; Xike Lu; Xun Zhang; Daqiang Sun
Journal:  J Cardiothorac Surg       Date:  2021-08-09       Impact factor: 1.637

3.  Coronary artery bypass grafting with concomitant resection for carcinoma of lung.

Authors:  Yangyang Zhang; Yanhu Wu; Biao Yuan; Xiang Liu; Sheng Zhao; Zhi Li; Yu Xia
Journal:  J Biomed Res       Date:  2010-01

4.  Comparison of perioperative characteristics and prognostic performance in patients with pulmonary lobectomy in early or later period after percutaneous coronary intervention.

Authors:  Tianyang Yun; Yue Tang; Bo Yang; Ke Li; Tao Liang; Dongtao Yin; Yang Liu
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.